Royalty Report: Drugs, Cancer, Therapeutic – Collection: 28726

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Wound Care
  • Biotechnology
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28726

License Grant
Licensor hereby grants Licensee an exclusive license, with the right to grant sub-licenses, under the OSI Patents and OSI Know-How, the right to manufacture, use and sell the Products for the Licensed Indications within the Territory.
License Property
'Compound' shall mean transforming growth factor Betas ('TGF-Betas') as described in the OSI Patents.

'OSI Patents' shall mean all of Licensor's right, title and interest in and to the patents relating to TGF-Betas set out in Schedule 1 to the Agreement and corresponding foreign patents or applications therefore, together with any patents issuing on the said applications, or any addition, continuation, continuation-in-part, division, reissue, renewal or extension based thereon (including any supplementary protection certificate based on the said patents).

'OSI Know-How' shall mean all information and material, technical data and other know-how invented, developed or acquired by, or under the control of any party hereto and which directly relates to the Compound or the Product, or to the development, manufacture or use of the same, including but not limited to chemical data, toxicological and other pre-clinical data, product forms and formulations, control assays and specifications and methods of preparation and stability data, all such data belonging to one party constituting that party's confidential information.

'Products' shall mean pharmaceutical preparations containing the Compound designed for administration to human beings which fall within the scope of the claims of the OSI Patents.

'Licensed Indications' shall mean (1) oral mucositis arising from the use of chemotherapy or radiation therapy in the treatment or prevention of cancer, and (2) topical or local (as opposed to systemic) application of the Products including, but not limited to, the healing of soft tissue wounds however caused, and the treatment of ophthalmic conditions and psoriasis, but excluding topical application in the gastrointestinal tract in the treatment or prevention of cancer or the management of side effects or adverse reactions arising from the use in the treatment or prevention of cancer of chemotherapy or radiation therapy; and also (3) all other indications deemed to be included in the Licensed.

IPSCIO Record ID: 7497

License Grant
Licensor grants a nonexclusive, worldwide license to Licensee to make, have made, use and sell TGF- beta 2 and TGF-beta Heterodimer as part of a Licensee's Licensed Product (i) for systemic administration for the treatment or prophylaxis of autoimmune diseases or conditions ('Autoimmune Use'), osteoporosis ('Osteoporosis Use'), and soft tissue wound healing (other than the healing of soft tissue wounds caused principally by vascular ischemia or reperfusion injury) ('Wound Healing Uses') and for bone marrow and stem cell protection allowing high dose cytotoxic chemotherapy in cancer patients ('Chemotherapy Use'), and (ii) for systemic or local or regional administration for direct anti-proliferative effects on solid cancerous tumors and lymphomas ('Cancer Use') and for the treatment or prophylaxis of prostatic hypertrophy ('Prostate Use') (collectively these six Uses are referred to as 'Systemic Uses').
Licensee may grant one sublicense under this license only to one other party in any country for each Systemic Use at any one time.
License Property
Licensor has certain patent rights relating to TGF-beta and the TGF-beta receptor.

'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.

'TGF-beta 2' shall mean a protein comprising the amino acid sequence hereto, and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.

'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.

'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.

Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.

'Phase I/II Clinical Trial' shall mean a controlled study in humans of the safety and efficacy of a Licensed Product for a particular indication or indications in subjects having the disease or condition under investigation.

IPSCIO Record ID: 230801

License Grant
The English Licensor hereby grants to Licensee and Licensee hereby accepts for the term of this License Agreement the non-transferable, exclusive, royalty-bearing license under Licensed Patents in the Field of Use to make, have made, use, lease, sell and otherwise dispose of Licensed Products in the Licensed Territory.

Licensor hereby grants to Licensee and Licensee hereby accepts for the term of this Agreement the non-transferable, exclusive, royalty-bearing license to use the Licensed Knowhow the Field of Use to make, have made, use, lease, sell and otherwise dispose of Licensed Products in the Licensed Territory.

License Property
The patents relate to pyridyl-steroid synthesis.

Licensed Product means any product made, sold, or otherwise disposed of by or on behalf of Licensee which: (i) falls within the scope of, or utilizes any method or process that falls within the scope of, the Licensed Patents; or (ii) incorporates, or is itself, the invention which is the subject of the Licensed Patents; or (iii) embodies or uses, or the design, manufacture, production or sale of which embodies or uses, any of the Licensed Knowhow.

Licensed Patents means: (i) the patents and patent applications (and any patents issuing therefrom) listed and all foreign counterpart patents and patent applications; (ii) all continuation, divisional, extension, reissue patents and reexamination certificates granted thereon, including Supplementary Protection Certificates; and (iii) patents and patent applications (and any patents issuing therefrom) that may hereafter be filed by Licensor relating or pertaining to any Licensed Knowhow, together with all continuations, divisional, extension, reissue patents and reexamination certificates granted thereon, including Supplementary Protection Certificates.

Licensee Technology means all inventions, ideas, conceptions or reductions-to-practice, patentable or not, information, works and data that are generated, identified, discovered, created, made or controlled by Licensee, its employees or a third party on behalf of Licensee, relating to the Licensed Product or its production, including, without limitation, technical data, knowhow, chemical compounds, biological material, reports, manufacturing processes, formulations, modes of delivery and methods of use, pre-clinical and clinical data, documentation relating to regulatory submissions and marketing authorizations (including any Investigational New Drug Applications, New Drug Applications and equivalent documents), and post-registration clinical trial information and data relating to the Licensed Products.

Licensed Knowhow means all trade secrets, inventions, confidential or proprietary information and data: (i) that is disclosed to Licensee by or at the direction of Licensor or Licensor’s assignor; (ii) that is owned by or licensed to Licensor or Licensor’s assignor at the time of such disclosure; and (iii) that relates to the inventions that are the subject matter of the Licensed Patents. Licensed Knowhow includes, without limitation, technical data, knowhow, chemical compounds, biological material, reports, manufacturing processes, formulations, modes of delivery and methods of use, pre-clinical and clinical data, documentation relating to regulatory submissions and marketing authorizations (including any Investigational New Drug Applications, New Drug Applications and equivalent documents), and post-registration clinical trial information and data relating to the Licensed Products.

Field of Use
Field of Use shall mean any therapeutic use that is intended to prevent, treat, ameliorate or cure a human disease, pathology or condition.

Licensee's goal is to perfonn clinical trials of abiraterone acetate that will support its indication as a second line therapy for patients with metastatic prostate cancer that has progressed following treatment with hormonal therapy that includes an LHRH agonist/antagonist and antiandrogen therapy.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.